TABLE 3

Current clinical trials on immunotherapy in the setting of surgery in early and locally advanced nonsmall cell lung cancer (NSCLC)

ClinicalTrials.gov IDPhaseNSCLC stageIO-drugProtocolPrimary
end-point
Induction therapy
 NCT03694236I/IIII/IIIADurvalumabChemoradiotherapy+durvalumab induction→surgerypCR
 NCT03237377IIIIIDurvalumab/
tremelimumab		Radiotherapy+durvalumab ± tremelimumab→surgerypCR
 NCT03197467IIII/IIIAPembrolizumabPembrolizumab induction→surgerySafety
 NCT02994576IIIB–IIIAAtezolizumabAtezolizumab induction→surgerySafety
 NCT03732664IIA–IIIANivolumabNivolumab induction→surgerySafety
 NCT04205552IIIB–IIIANivolumab/
relatlimab		Nivolumab ± relatlimab induction→surgeryFeasibility
 NCT02259621IIIB–IIIANivolumab/
ipilimumab		Nivolumab ± ipilimumab induction→surgerySafety
 NCT04348292II–IIIADurvalumab/
sirolimus		Durvalumab+sirolimus induction→surgerySafety
Combined induction and adjuvant therapy
 NCT03871153IIResectable IIIDurvalumabChemoradiotherapy+durvalumab induction→surgery→durvalumab consolidationpCR
 NCT04062708IIIIIDurvalumabChemotherapy+durvalumab induction→surgery→radiotherapy→durvalumab consolidationpCR
 NCT03871153IIResectable IIIDurvalumabChemotherapy+durvalumab induction→radiotherapy+durvalumab→surgery→
durvalumab consolidation		pCR
 NCT04202809IIIIIA–BDurvalumabChemotherapy induction→chemoradiotherapy ± durvalumab→surgery if resectablePFS
 NCT02818920IIIB–IIIAPembrolizumabPembrolizumab induction→surgery→pembrolizumab consolidationSurgical feasibility rate
 NCT03838159IIIIIANivolumabArm 1: chemotherapy+nivolumab induction→surgery→nivolumab consolidation
Arm 2: chemotherapy induction→surgery		pCR
 NCT02572843IIIIIADurvalumabChemotherapy+durvalumab induction→surgery→durvalumab consolidationDFS
 NCT04025879#IIIII–IIIBNivolumabChemotherapy ± nivolumab→surgery→nivolumab consolidation or observationDFS
Adjuvant therapy
 NCT02595944#IIIIB–IIIANivolumabSurgery→chemotherapy→nivolumab consolidation or observationDFS, OS

Data obtained from www.clinicaltrials.gov on 7 August 2020. IO: immune-oncology; pCR: pathological complete response; PFS: progression-free survival; DFS: disease-free survival; OS: overall survival. #: phase III trials.